Trials / Not Yet Recruiting
Not Yet RecruitingNCT07104110
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLH12016 | oral AR PROTAC |
| DRUG | abiraterone acetate | oral CYP17 inhibitor |
| DRUG | enzalutamide | oral androgen receptor inhibitor |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2027-10-01
- Completion
- 2028-10-01
- First posted
- 2025-08-05
- Last updated
- 2025-08-05
Source: ClinicalTrials.gov record NCT07104110. Inclusion in this directory is not an endorsement.